Aquestive gains after patent wins for Anaphylm (AQST:NASDAQ)

Core Viewpoint - Shares of Aquestive Therapeutics rose following the announcement of two new patents for its allergy therapy Anaphylm, which is currently under FDA review [4]. Company Summary - Aquestive Therapeutics is based in Warren, New Jersey, and operates in the biopharmaceutical sector [4]. - The newly issued patents cover the company's allergy therapy, Anaphylm, indicating potential for enhanced market position and intellectual property protection [4].